This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

ASCO, CHICAGO, IL, USA, 31 May-4 JUNE 2019

A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (MDM2-p53 antagonist) in adult patients with advanced or metastatic solid tumors.​

Curtis Chong, Todd Michael Bauer, Scott Andrew Laurie, Manish R. Patel, Noboru Yamamoto, Teffany Davenport, Junxian Geng, Neil Gibson, Markus P. Vallaster, Patricia LoRusso

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

MDM2-P53 ANTAGONIST

inoncology.com

FOR HEALTHCARE PROFESSIONALS ONLY.

 

image